Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines

Ku 蛋白与激活蛋白 2 转录因子相互作用,导致乳腺癌细胞系中 ERBB2 过表达

阅读:17
作者:Grégory Nolens, Jean-Christophe Pignon, Benjamin Koopmansch, Benaïssa Elmoualij, Willy Zorzi, Edwin De Pauw, Rosita Winkler

Conclusions

Ku proteins in interaction with AP-2 (alpha and gamma) contribute to increased ERBB2 mRNA and protein levels in breast cancer cells.

Methods

Ku proteins were identified as AP-2alpha interacting proteins by glutathione serine transferase (GST)-pull down followed by mass spectrometry. Transfection of the cells with siRNA, expression vectors and reporter vectors as well as chromatin immunoprecipitation (ChIP) assay were used to ascertain the implication of Ku proteins on ERBB2 expression.

Results

Nuclear proteins from BT-474 cells overexpressing AP-2alpha and AP-2gamma were incubated with GST-AP2 or GST coated beads. Among the proteins retained specifically on GST-AP2 coated beads Ku70 and Ku80 proteins were identified by mass spectrometry. The contribution of Ku proteins to ERBB2 gene expression in BT-474 and SKBR3 cell lines was investigated by downregulating Ku proteins through the use of specific siRNAs. Depletion of Ku proteins led to downregulation of ERBB2 mRNA and protein levels. Furthermore, reduction of Ku80 in HCT116 cell line decreased the AP-2alpha activity on a reporter vector containing an AP-2 binding site linked to the ERBB2 core promoter, and transfection of Ku80 increased the activity of AP-2alpha on this promoter. Ku siRNAs also inhibited the activity of this reporter vector in BT-474 and SKBR3 cell lines and the activity of the ERBB2 promoter was further reduced by combining Ku siRNAs with AP-2alpha and AP-2gamma siRNAs. ChIP experiments with chromatin extracted from wild type or AP-2alpha and AP-2gamma or Ku70 siRNA transfected BT-474 cells demonstrated Ku70 recruitment to the ERBB2 proximal promoter in association with AP-2alpha and AP-2gamma. Moreover, Ku70 siRNA like AP-2 siRNAs, greatly reduced PolII recruitment to the ERBB2 proximal promoter. Conclusions: Ku proteins in interaction with AP-2 (alpha and gamma) contribute to increased ERBB2 mRNA and protein levels in breast cancer cells.

文献解析

 

​1. 文献背景信息​

  • ​标题/作者/期刊/年份​​:

    • 标题:Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines

    • 作者:Grégory Nolens等

    • 期刊:Breast Cancer Research(IF=6.100)

    • 年份:2009年

    • ​权威性与时效性​​:发表于中高影响力期刊,虽年份较早,但ERBB2(HER2)调控机制仍是乳腺癌研究热点。

  • ​研究领域与背景​​:

    • ​分支领域​​:乳腺癌中ERBB2/HER2的转录调控机制。

    • ​研究现状​​:ERBB2过表达是20-30%乳腺癌的驱动因素,但调控其表达的转录因子(如AP-2)的协同作用机制尚不明确。

  • ​研究动机​​:

    • 填补空白:AP-2α/γ已知调控ERBB2,但未揭示其如何与Ku蛋白协同促进ERBB2过表达。


​2. 研究问题与假设​

  • ​核心问题​​:Ku蛋白如何与AP-2转录因子相互作用并影响ERBB2在乳腺癌中的表达?

  • ​假设​​:Ku70/Ku80通过与AP-2α/γ结合,增强ERBB2启动子活性,导致mRNA和蛋白水平升高。


​3. 研究方法学与技术路线​

  • ​实验设计​​:

    • ​GST-pull down + 质谱​​:鉴定AP-2α互作蛋白(Ku70/Ku80)。

    • ​功能验证​​:siRNA敲降Ku蛋白(BT-474/SKBR3细胞),检测ERBB2表达变化。

    • ​报告基因实验​​:ERBB2启动子活性分析(AP-2结合位点+核心启动子)。

    • ​ChIP​​:验证Ku70与AP-2α/γ在ERBB2启动子的共定位。

  • ​关键技术​​:

    • 细胞模型:ERBB2高表达乳腺癌细胞(BT-474/SKBR3)。

    • 方法创新:首次揭示Ku蛋白在ERBB2转录调控中的非经典功能(传统认知中Ku蛋白参与DNA修复)。


​4. 结果与数据解析​

  • ​主要发现​​:

          ​​互作验证​​:质谱鉴定Ku70/Ku80为AP-2α/γ结合蛋白(图1)。

          ​​功能影响​​:siRNA敲降Ku70/Ku80显著降低ERBB2 mRNA和蛋白(图2-3,p<0.05)。

          ​​机制证据​​:

      • ChIP显示Ku70与AP-2α/γ共定位于ERBB2启动子(图4)。

      • Ku80过表达增强AP-2α对ERBB2启动子的激活(图5)。

  • ​数据验证​​:

    • 多细胞系验证(BT-474/SKBR3/HCT116)。

    • 交叉实验(siRNA+报告基因+ChIP)。

  • ​局限性​​:

    • 未解析Ku蛋白具体结构域如何与AP-2结合。

    • 临床样本中Ku-ERBB2关联性未验证。


​5. 讨论与机制阐释​

  • ​机制模型​​:Ku蛋白通过招募AP-2α/γ至ERBB2启动子,促进PolII募集,增强转录(图6)。

  • ​与既往研究对比​​:

    • 支持AP-2调控ERBB2的经典理论,但补充Ku蛋白的协同作用(新机制)。

  • ​未解决问题​​:

    • Ku-AP-2互作是否受上游信号通路(如HER2自身反馈)调控?

    • 其他癌症类型中是否存在类似机制?


​6. 创新点与学术贡献​

  • ​理论创新​​:揭示Ku蛋白在转录调控中的非经典角色(超越DNA修复功能)。

  • ​技术贡献​​:GST-pull down与报告基因联用策略可推广至其他转录因子研究。

  • ​实际价值​​:为HER2阳性乳腺癌的靶向治疗提供新潜在靶点(如干扰Ku-AP-2互作)。


​总结​​:该研究通过多方法验证了Ku蛋白与AP-2协同调控ERBB2的机制,为乳腺癌靶向治疗提供了新视角,但需进一步临床转化研究。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。